Trial Outcomes & Findings for Probiotics for Chalaziosis Treatment in Children (NCT NCT04322500)

NCT ID: NCT04322500

Last Updated: 2020-05-05

Results Overview

change in the time taken for complete resolution of chalaziosis (complete disappearance of the eyelid mass lesions)

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

26 participants

Primary outcome timeframe

3 months

Results posted on

2020-05-05

Participant Flow

Participant milestones

Participant milestones
Measure
Group A: Conservative
conservative treatment conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
Group B: Probiotics
in addition to the conservative treatment they receive a probiotics mixture (ST10, LLCO2 and LDB01) probiotics: use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
Overall Study
STARTED
13
13
Overall Study
COMPLETED
13
13
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Probiotics for Chalaziosis Treatment in Children

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Group A: Conservative
n=13 Participants
conservative treatment conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
Group B: Probiotics
n=13 Participants
in addition to the conservative treatment they receive a probiotics mixture (ST10, LLCO2 and LDB01) probiotics: use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
Total
n=26 Participants
Total of all reporting groups
Age, Continuous
7.9 years
STANDARD_DEVIATION 1.2 • n=5 Participants
8.6 years
STANDARD_DEVIATION 1.9 • n=7 Participants
8.3 years
STANDARD_DEVIATION 1.5 • n=5 Participants
Sex: Female, Male
Female
9 Participants
n=5 Participants
8 Participants
n=7 Participants
17 Participants
n=5 Participants
Sex: Female, Male
Male
4 Participants
n=5 Participants
5 Participants
n=7 Participants
9 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
White
13 Participants
n=5 Participants
13 Participants
n=7 Participants
26 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
Italy
13 participants
n=5 Participants
13 participants
n=7 Participants
26 participants
n=5 Participants

PRIMARY outcome

Timeframe: 3 months

change in the time taken for complete resolution of chalaziosis (complete disappearance of the eyelid mass lesions)

Outcome measures

Outcome measures
Measure
Group A: Conservative
n=13 Participants
conservative treatment conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
Group B: Probiotics
n=13 Participants
in addition to the conservative treatment they receive a probiotics mixture (ST10, LLCO2 and LDB01) probiotics: use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
Time Taken for a Complete Resolution of the Chalaziosis
51.2 days
Standard Deviation 12.4
28.4 days
Standard Deviation 10.8

PRIMARY outcome

Timeframe: 3 months

complete ophthalmological evaluation was done weekly during the first month and then monthly in order to evaluate possible recurrences (presence of a new eyelid mass lesion)

Outcome measures

Outcome measures
Measure
Group A: Conservative
n=13 Participants
conservative treatment conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
Group B: Probiotics
n=13 Participants
in addition to the conservative treatment they receive a probiotics mixture (ST10, LLCO2 and LDB01) probiotics: use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
Number of Recurrences
0 recurreces
0 recurreces

Adverse Events

Group A: Conservative

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group B: Probiotics

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Prof. Ciro Costagliola

University of Molise

Phone: +39 0874 404861/ 0874 404896

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place